
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics is currently on track with its clinical trials and development of ficerafusp alfa, which has the potential to be a transformative therapy for patients with solid tumors. With additional data from trials expected in 2026, as well as plans for an interim analysis in 2027, the company has potential catalysts for future growth. However, in the bear case scenario, underwhelming clinical results and limited differentiation could lower the probability of success for ficerafusp alfa, resulting in a lower fair value of $11. The stock's closing price over the past 12 months and projected prices in bull, base, and bear cases suggest potential upside for investors.
Bears say
Bicara Therapeutics is facing a highly competitive landscape in the 3L+ MSS mCRC market, with several early-stage programs showing promising efficacy and durability data. Bicara's hybrid antibody, ficerafusp alfa, is being positioned as a potential solution to this challenge, based on its dual EGFR/TGF-b inhibition mechanism. However, there are concerns around the safety profile of ficerafusp alfa, particularly in long-term maintenance use. The bull scenario for Bicara hinges on its ability to prove the efficacy and safety of ficerafusp alfa in various treatment contexts, which could result in significant market share and a $42 fair value for the company.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares